Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles

被引:155
作者
Sawkar, AR
Adamski-Werner, SL
Cheng, WC
Wong, CH
Beutler, E
Zimmer, KP
Kelly, JW [1 ]
机构
[1] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[4] Univ Munster, D-48149 Munster, Germany
来源
CHEMISTRY & BIOLOGY | 2005年 / 12卷 / 11期
基金
美国国家科学基金会;
关键词
D O I
10.1016/j.chembiol.2005.09.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gaucher disease is a lysosomal storage disorder caused by deficient glucocerebrosidase activity. We have previously shown that the cellular activity of the most common Gaucher disease-associated glucocerebrosidase variant, N370S, is increased when patient-derived cells are cultured with the chemical chaperone N-nonyl-deoxynojirimycin. Chemical chaperones stabilize proteins against misfolding, enabling their trafficking from the endoplasmic reticulum. Herein, the generality of this therapeutic strategy is evaluated with other glucocerebrosidase variants and with additional candidate chemical chaperones. Improved chemical chaperones are identified for N370S glucocerebrosidase. Moreover, we demonstrate that G202R, a glucocerebrosidase variant that is known to be retained in the endoplasmic reticulum, is also amenable to chemical chaperoning. The L444P variant is not chaperoned by any of the active site-directed molecules tested, likely because this mutation destabilizes a domain distinct from the catalytic domain.
引用
收藏
页码:1235 / 1244
页数:10
相关论文
共 48 条
[1]  
Andersch J, 2001, CHEM-EUR J, V7, P3744, DOI 10.1002/1521-3765(20010903)7:17<3744::AID-CHEM3744>3.0.CO
[2]  
2-3
[3]   EXPEDITIOUS SYNTHESIS OF AZASUGARS BY THE DOUBLE REDUCTIVE AMINATION OF DICARBONYL SUGARS [J].
BAXTER, EW ;
REITZ, AB .
JOURNAL OF ORGANIC CHEMISTRY, 1994, 59 (11) :3175-3185
[4]   Pharmacological chaperone action on G-protein-coupled receptors [J].
Bernier, V ;
Bichet, DG ;
Bouvier, M .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) :528-533
[5]   FAILURE OF ALGLUCERASE INFUSED INTO GAUCHER DISEASE PATIENTS TO LOCALIZE IN MARROW MACROPHAGES [J].
BEUTLER, E ;
KUHL, W ;
VAUGHAN, LM .
MOLECULAR MEDICINE, 1995, 1 (03) :320-324
[6]  
BEUTLER E, 1993, AM J HUM GENET, V52, P85
[7]   Synthesis of stable analogues of glyceroglycolipids [J].
Cipolla, L ;
Nicotra, F ;
Vismara, E ;
Guerrini, M .
TETRAHEDRON, 1997, 53 (17) :6163-6170
[8]   PARTIAL ENZYME DEFICIENCIES - RESIDUAL ACTIVITIES AND THE DEVELOPMENT OF NEUROLOGICAL DISORDERS [J].
CONZELMANN, E ;
SANDHOFF, K .
DEVELOPMENTAL NEUROSCIENCE, 1984, 6 (01) :58-71
[9]   Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis [J].
Cox, T ;
Lachmann, R ;
Hollak, C ;
Aerts, J ;
van Weely, S ;
Hrebícek, M ;
Platt, F ;
Butters, T ;
Dwek, R ;
Moyses, C ;
Gow, I ;
Elstein, D ;
Zimran, A .
LANCET, 2000, 355 (9214) :1481-1485
[10]   The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease:: A position statement [J].
Cox, TM ;
Aerts, JMFG ;
Andria, G ;
Beck, M ;
Belmatoug, N ;
Bembi, B ;
Chertkoff, R ;
Vom Dahl, S ;
Elstein, D ;
Erikson, A ;
Giralt, M ;
Heitner, R ;
Hollak, C ;
Hrebicek, M ;
Lewis, S ;
Mehta, A ;
Pastores, GM ;
Rolfs, A ;
Miranda, MCS ;
Zimran, A .
JOURNAL OF INHERITED METABOLIC DISEASE, 2003, 26 (06) :513-526